Reading RPID? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RPID free→Reading RPID? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RPID free→QuarterlyIQ Insights · RPID
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. Underwriting Agreement On May 18, 2026, Rapid Micro Biosystems, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC and Lake Street Capital Markets LLC, as representatives of the several underwriters named therein (the “Underwriters”) relating to an underwritten offering (the “Offering”) of (i) 3,581,000 shares (the “Shares”) of the Company’s Class A common stock, $0.01 par value pe…
Results of Operations and Financial Condition. On May 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its first quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 1…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 23, 2026, Mr. John Wilson, Chief Operating Officer of Rapid Micro Biosystems, Inc. (the “Company”), notified the Company of his intention to depart from the Company, effective April 10, 2026, in order to spend more time with his family. Mr. Wilson’s departure is not the result of any disagreement with the Company on any matter relating…
Results of Operations and Financial Condition. On March 12, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its its fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
Results of Operations and Financial Condition. On January 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit…
Results of Operations and Financial Condition. On November 7, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of…
Results of Operations and Financial Condition. On August 12, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its second quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Secti…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. On August 8, 2025 (the “Closing Date”), Rapid Micro Biosystems, Inc. (the "Company") entered into a Loan and Security Agreement (the “LSA”) with the lenders party thereto (the “Lenders”) and Trinity Capital Inc., as administrative agent and collateral agent (the “Agent”). Under the LSA, the Lenders agreed to extend debt capital to the Company, in the form of a term loan, in tranches totaling an aggregate principal amount of up to $45.0 million avail…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 22, 2025, Jeffrey Schwartz notified Rapid Micro Biosystems, Inc. (the "Company") of his resignation from the board of directors of the Company and all committees thereof, effective as of May 22, 2025. Mr. Schwartz was a Class II director and served as the chair of the nominating and corporate governance committee. Mr. Schwartz’s resignation…
Results of Operations and Financial Condition. On May 9, 2025, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 1…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.